MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) issued its quarterly earnings results on Tuesday. The company reported ($0.54) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.

Shares of MabVax Therapeutics Holdings (MBVX) traded up $0.01 during midday trading on Thursday, reaching $0.65. 94,403 shares of the company traded hands, compared to its average volume of 242,668. The company has a debt-to-equity ratio of 38.83, a quick ratio of 0.28 and a current ratio of 0.28. MabVax Therapeutics Holdings has a 1-year low of $0.43 and a 1-year high of $4.50.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at

About MabVax Therapeutics Holdings

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Receive News & Ratings for MabVax Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.